
Tirzepatide
Dual GLP-1/GIP Receptor Co-Agonist
C₂₂₅H₃₄₈N₄₈O₆₈ · 4,813.5 Da
GIP-based dual agonist incorporating a GLP-1 receptor-binding motif. Features a C20 fatty diacid moiety enabling reversible albumin binding and extended circulatory half-life.
- Form
- Lyophilized powder
- Purity
- 99.96%
- Stock
- In stock
- Sizes available
- 10mg
Specification
- Sizes available
- 10mg ($64.95)
- Form
- Lyophilized powder
- Category
- Metabolic Research
- Molecular class
- Dual GLP-1/GIP Receptor Co-Agonist
- Molecular formula
- C₂₂₅H₃₄₈N₄₈O₆₈
- Molecular weight
- 4,813.5 Da
- Purity
- 99.96%
Certificate of Analysis
- Test Method
- LCMS-UV
- Laboratory
- ACS Peptide Testing Labs
- Test Date
- 2026-07-28
Composition, targets and analytical record
The structural record for the material as supplied, and the analytical figures returned for the lot on the certificate.
Tirzepatide is a synthetic 39-residue peptide of molecular formula C₂₂₅H₃₄₈N₄₈O₆₈, with an average molecular mass of 4813.53 Da and a monoisotopic mass of 4810.5249 Da. The sequence opens Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr and closes Gly-Ala-Pro-Pro-Pro-Ser as a C-terminal amide. Alpha-aminoisobutyric acid, a non-proteinogenic alpha,alpha-disubstituted residue, occupies positions 2 and 13; every other position is proteinogenic.
- 1Tyr
- 2Aib
- 3Glu
- 4Gly
- 5Thr
- 6Phe
- 7Thr
- 8Ser
- 9Asp
- 10Tyr
- 11–12⋯
- 13Aib
- 14–19⋯
- 20Lys
- 21–33⋯
- 34Gly
- 35Ala
- 36Pro
- 37Pro
- 38Pro
- 39Ser
The epsilon-amine of Lys20 carries a branched acyl assembly consisting of an eicosanedioic (C20 alpha,omega-dicarboxylic) acyl group linked through a gamma-glutamate spacer and two consecutive 2-[2-(2-aminoethoxy)ethoxy]acetyl (AEEA) units. That assembly contributes C₃₇H₆₅N₃O₁₂ to the intact composition, the unmodified backbone accounting for the remainder. Assembling the formula from the sequence and the four amide bonds of the acyl-spacer chain reproduces the deposited formula atom for atom, which provides an internal check on both the sequence assignment and the substitution site.
The molecule belongs to the incretin-family peptide analogues of the glucagon/secretin peptide superfamily. Two receptor entries are named against it: the gastric inhibitory polypeptide receptor (UniProt P48546) and the glucagon-like peptide 1 receptor (UniProt P43220). It is described in ChEMBL as a dual GIP and GLP-1 receptor agonist peptide.
Structurally the compound is separated from retatrutide by the position and composition of its lipid substituent, Lys20 with two AEEA spacer units against Lys17 with one, and by position 13, which is alpha-aminoisobutyric acid here and alpha-methyl-leucine in retatrutide. It is separated from the native 42-residue gastric inhibitory polypeptide by length, by the two Aib substitutions, by the C-terminal amide and by the presence of the acyl chain, none of which occur in the native sequence. The 82.11 Da average-mass gap to retatrutide and the far larger gap to unmodified incretin sequences make identity assignment by mass spectrometry straightforward.
- Acyl chain attachment
- RetatrutideLys17
- TirzepatideLys20
- AEEA units in spacer
- Retatrutide1
- Tirzepatide2
- Position 13
- Retatrutideα-methyl-Leu
- TirzepatideAib
Analytical specification
ACS Peptide Testing Labs · 2026-07-28 · AAHW066The lot supplied for Tirzepatide was assayed by ACS Peptide Testing Labs on 2026-07-28 under accession AAHW066. Purity is reported as 99.96% by LCMS-UV, expressed as the percentage of total UV peak area attributable to the target compound. Identity is a separate determination and was returned as: Confirmed (LCMS-UV mass ID). A sample can be highly pure and still be the wrong molecule, which is why both results appear on the certificate.
The material was recorded as White powder. The sequence corresponds to a molecular formula of C₂₂₅H₃₄₈N₄₈O₆₈ and a calculated mass of 4,813.5 Da.
Endotoxin was outside the scope of this assay and is reported as N/A. Peak-area percentage is also not the same as absolute mass purity: material that does not absorb at the detection wavelength is not represented in the figure.
References
In-vitro and preclinical literature. These are provided as reading for laboratory context and are not claims about the material.
- 01PubChem CID 156588324 — Molecular formula C225H348N48O68 and PubChem CID; Average and monoisotopic masses computed from the PubChem molecular formula using IUPAC standard atomic weights and principal isotope masses
- 02ChEMBL CHEMBL4297839 — Primary sequence and positions of the three modified residues; Synonyms LY3298176 and BG-121; Classification as a dual GIP and GLP-1 receptor agonist peptide
- 03UniProt P48546 — Target name: gastric inhibitory polypeptide receptor
- 04UniProt P43220 — Target name: glucagon-like peptide 1 receptor
This material is supplied strictly for in-vitro laboratory research. It is not a drug, food or supplement, and is not for human or veterinary use, diagnosis, or consumption.
Related compounds
View catalog
Retatrutide
15mg · Lyophilized powder

BPC-157
10mg · Lyophilized powder

Tesamorelin
10mg · Lyophilized powder

NAD+
1000mg · Lyophilized powder